Combined hepatocholangiocarcinoma: Case-series and review of literature

International Journal of Gastrointestinal Cancer

Volumn 37, Issue 1, 2006, Pages 27-34

  Bhagat, Vishal ^a   Javle, Milind ^a   Yu, Jihnhee ^b   Agrawal, Aarti ^a   Gibbs, John F ^a   Kuvshinoff, Boris ^a   Nava, Enriquetta ^a   Iyer, Renuka ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Hepatocholangiocarcinoma

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; INTERFERON;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA; CHEMOEMBOLIZATION; CHOLELITHIASIS; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMBINED HEPATOCHOLANGIOCARCINOMA; FEMALE; HEPATITIS B; HEPATITIS C; HEPATOMEGALY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR;

AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CHOLELITHIASIS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33846957677     PISSN: 15373649     EISSN: 15590739     Source Type: Journal    
DOI: 10.1385/IJGC:37:1:27     Document Type: Review

References (37)

1. Molmenti EP, Marsh JW, Dvorchik I, Oliver JH 3rd, Madariaga J, Iwatsuki S: Hepatobiliary malignancies. Primary hepatic malignant neoplasms. Surg Clin North Am 1999; 79(1):43-57.
2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9(2):191-211.
3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Sem Liver Dis 2004;24(2):115-125.
4. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40(3):472-477.
5. Wu PC, Lai VC, Fang JW, Gerber MA, Lai CL, Lau JY. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999;31(5):965-966.
6. Lee CC, Wu CY, Chen JT, Chen GH. Comparing combined hepatocellular cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepato Gastroenterology 2002;49(48):1487-1490.
7. Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jp J Clinical Oncol 2003;33(6):283-287.
8. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005;189(1):120-125.
9. Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer2002;94(7):2040-2046.
10. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular- cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol 1998;13(1):34-40.
11. National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services. Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies). Natl Toxicol Program Tech Rep Ser 2002;(504):1-357.
12. National Toxicology Program . NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 2000;491:1-412.
13. Johnson JD, Ryan MJ, Toft JD II, Graves SW, et al. Two-year toxicity and carcinogenicity study of methyleugenol in F344/N rats and B6C3F(1) mice. J Agric Food Chem 2000;48(8):3620-3632.
14. Morcos M, Dubois S, Bralet MP, Belghiti J, Degott C, Terris B. Primary liver carcinoma in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol 2001;116(5):738-743.
15. Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998 Jun;22(6):742-748.
16. Sonakul D, Koompirochana C, Chinda K, Stitnimakarn T. Hepatic carcinoma with opisthorchiasis. Southeast Asian J Trop Med Public Health 1978;9(2):215-219.
17. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40(2):298-304.
18. Imai Y, Oda H, Arai M, et al. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jp J Cancer Res 1996;87(10):1056-1062.
19. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, et al. Clinical and molecular analysis of combined hepatocellularcholangiocarcinomas. J Hepatol 2004;41(2):292-298.
20. Haratake J, Hashimoto H. An immunohistochemical analysis of 13 cases with combined hepatocellular and cholangiocellular carcinoma. Liver 1995;15(1):9-15.
21. Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. Aclinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 1996;11(8):758-764.
22. Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular- cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 2002;26(8):989-997.
23. Varnholt H, Asayama Y, Aishima S, Taguchi K, Sugimachi K, Tsuneyoshi M. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma. Oncology Reports 2002;9(1):35-41.
24. Asayama Y, Taguchi Ki K, Aishima Si S, Nishi H, Masuda K, Tsuneyoshi M. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alphacatenin and beta-catenin. Liver 2002;22(1):43-50.
25. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985;55(1):124-135.
26. Brumm C, Schulze C, Charels K, Morohoshi T, Kloppel G. The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology 1989;14(5):503-513.
27. Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR. Am J Roentgenol 2005;184(4):1157-1162.
28. Santoro E, Sacchi M, Carboni F, Santoro R, Scardamaglia F. Diagnostic and surgical features of Klatskin tumors. Chirurgia Italiana 1999;51(1):1-7.
29. Liu YX. [Transcatheter chemoembolization combined with hepatectomy for primary hepatic carcinoma. Aclinical and pathological study]. [Chinese] Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery] 1992;30(6):342-345, 382.
30. Monden M, Sakon M, Gotoh M, et al. Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions. Cancer Chemother Pharmacol 1992;31 Suppl:S38-44.
31. Inoue H, Hori A, Satake M, et al. [Liver abscess formation after treatment of liver cancer by arterial injection using adriamycin/mitomycin C oil suspension (ADMOS)]. [Japanese] Nippon Igaku Hoshasen Gakkai Zasshi-Nippon Acta Radiologica 1992;52(2):155-163.
32. Kokudo N, Makuuchi M. Current role of portal vein embolization/hepatic artery chemoembolization. Surg Clin North Am 2004;84(2):643-657.
33. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996;149(4):1167-1175.
34. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol 2005;23(10):2332-2338.
35. Shimoyama T, Shimizu T, Miyashita K, et al. [Study of combined hepatocellular and cholangiocarcinoma]. [Japanese] Gan to Kagaku Ryoho [Jp J Cancer Chemother] 1993;20(2):295-298.
36. Liu CL, Fan ST, Lo CM, Ng IO, Lam CM, Poon RT, Wong J. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg 2003;138(1):86-90.
37. Jeong BJ, Hyun DH, Lee KW, et al. [A case of sarcomatoid combined hepatocellular-cholangiocarcinoma]. [Korean] Korean Journal of Gastroenterology/Taehan Sohwagi Hakhoe Chi 2004;43(1):56-60.